

## Appendix

### Members of the 'AGO Breast Committee' in alphabetical order:

Prof. Dr. Ute-Susann Albert  
Krankenhaus Nordwest GmbH,  
Frankfurt/M.

Dr. Ingo Bauerfeind  
Frauenklinik im Klinikum Landshut

PD Dr. Joachim Bischoff  
Klinikum Dessau

Prof. Dr. Jens-Uwe Blohmer  
Charité, Berlin

Prof. Dr. Wilfried Budach  
Universitätsklinikum Düsseldorf

Prof. Dr. Peter Dall  
Städtisches Klinikum Lüneburg

Prof. Dr. Ingo J. Diel  
CGG Klinik Mannheim

Prof. Dr. Tanja Fehm  
Universitätsfrauenklinik Düsseldorf

PD Dr. Nikos Fersis  
Klinikum Bayreuth

Prof. Dr. Michael Friedrich  
Helios-Klinikum Krefeld

Prof. Dr. Bernd Gerber  
Universitäts-Frauenklinik Rostock

Prof. Dr. Volker Hanf  
Klinikum Fürth

Prof. Dr. Nadia Harbeck  
Breast Center, Dept. OB&GYN, University  
of Munich

Prof. Dr. Jens Huober  
Universitätsklinikum Ulm

Prof. Dr. Christian Jackisch  
Klinikum Offenbach

Prof. Dr. Wolfgang Janni  
Universitätsklinikum Ulm

Prof. Dr. Hans H. Kreipe  
Medizinische Hochschule Hannover

Prof. Dr. Thorsten Kühn  
Klinikum Esslingen

PD Dr. Sherko Kümmel  
Evang. Huysens-Stiftung, Essen

PD Dr. Cornelia Liedtke  
Universitätsklinikum Schleswig-Holstein,  
Lübeck

Prof. Dr. Sibylle Loibl  
GBG Forschungs GmbH, Neu-Isenburg

Prof. Dr. Hans-Joachim Lück  
Gynäkologisch-Onkologische Praxis  
Hannover

Prof. Dr. Michael P. Lux  
Universitätsfrauenklinik Erlangen

Prof. Dr. Nicolai Maass  
Universitätsklinikum Schleswig-Holstein,  
Kiel

Prof. Dr. Gunter von Minckwitz  
GBG Forschungs GmbH, Neu-Isenburg

Prof. Dr. Volker Möbus  
Städt. Kliniken Frankfurt-Höchst

Prof. Dr. Volkmar Müller  
Universitätsklinikum Hamburg-Eppendorf

Prof. Dr. Christoph Mundhenke  
Universitätsklinikum Schleswig-Holstein,  
Kiel

Prof. Dr. Ulrike Nitz  
Bethesda Krankenhaus Mönchengladbach

Dr. Mahdi Rezai  
Luisenkrankenhaus, Düsseldorf

Prof. Dr. Achim Rody  
Universitätsklinikum Schleswig-Holstein,  
Lübeck

Prof. Dr. Anton Scharl  
Klinikum St. Marien, Amberg

Prof. Dr. Marcus Schmidt  
Universitätsfrauenklinik Mainz

Prof. Dr. Rita Schmutzler  
Klinikum der Universität zu Köln

Prof. Dr. Andreas Schneeweiss  
Gynäkologische Onkologie, Heidelberg

Prof. Dr. Ingrid Schreer  
Hamburg

Prof. Dr. Florian Schütz  
Klinikum der Ruprecht-Karl-Univ.  
Heidelberg

Prof. Dr. H. Peter Sinn  
Klinikum der Ruprecht-Karl-Univ.  
Heidelberg

Prof. Dr. Erich Solomayer  
Universitätsklinikum des Saarlandes,  
Homburg

Prof. Dr. Elmar Stickeler  
Universitätsklinikum Aachen

PD Dr. Marc Thill  
Agaplesion Markus  
Krankenhaus Frankfurt/M.

Prof. Dr. Christoph Thomssen  
Universitätsklinik u. Poliklinik für  
Gynäkologie, Halle/Saale

Prof. Dr. Michael Untch  
Frauenklinik / interdisziplinäres  
Brustzentrum Helios-Kliniken Berlin

Prof. Dr. Frederik Wenz  
Universitätsklinikum Mannheim

PD Dr. Isabell Witzel  
Brustzentrum Universitätsklinik Hamburg-  
Eppendorf

**Associated members of the DEGRO**

Prof. Dr. Petra Feyer  
Vivantes Klinikum Neukölln, Berlin

Prof. Dr. Dirk Rades  
Universitätsklinikum Schleswig-Holstein,  
Lübeck

**Supplemental Figures**


### Follow-Up Care for Breast Cancer

Recommendations for asymptomatic pts.  
(modified ASCO-ACS guidelines 2016, NCCN 1.2016 guidelines and S3 national German guideline 2012)

Clinical follow-up	Follow-Up*					Screening
	1	2	3	4	5	
Years after primary therapy						> 6
History, physical examination, counseling	Inv.: every 3 months		Inv.: every 6 months			Inv.: every 12 months
Self-examination	monthly					
Imaging modalities and biochemistry	Indicated only by complaints, clinical findings or suspicion of recurrence					
Mammography and sonography	BCT**	Ipsilateral: every 12 months contralateral: every 12 months		on both sides: every 12 months		
	Mastectomy	contralateral every 12 months				

\* Continued follow-up visits if still on adjuvant treatment  
\*\* In pts with breast-conserving therapy (BCT): First mammography 1 year after initial mammography or at least 8 months after completion of radiotherapy

Supplemental fig. 1. Follow-up care for breast cancer.



**Supplemental fig. 2.** Treatment recommendations for postmenopausal patients with metastatic breast cancer after adjuvant AI.

MBC HER2-negative/HR-positive: Cytotoxic Therapy after adjuvant Taxane and Anthracycline Treatment		Oxford / AGO LoE / GR
> Experimental therapies within studies		++
> Capecitabine	2b B	++
> Eribulin	1b B	++
> Vinorelbine	2b B	++
> (Peg)-liposomal Doxorubicin	2b B	+
> Taxane re-challenge	2b B	+
> Anthracycline re-challenge	3b C	+
> Metronomic therapy (eg. cyclophos. + MTX)	2b B	+
> Gemcitabine + Cisplatin / Carboplatin	2b B	+/-
> Gemcitabine + Capecitabine	2b B	+/-
> Gemcitabine + Vinorelbine*	1b B	-

**Supplemental fig. 3.** Cytotoxic therapy after adjuvant taxane and anthracycline treatment in HER2-negative/HR-positive breast cancer.

Granulocyte Colony-stimulating Factors		Oxford / AGO LoE / GR
> Primary prophylaxis for expected febrile neutropenia (FNP)		
> If expected risk for FNP 10–20%	1b B	+/-
> In case of individual risk factors	3b C	+
> If expected risk for FNP >20% (e.g. DAC, dose-dense CT)	1a A	++
> Secondary prophylaxis during chemotherapy (previous FNP or neutropenia grade IV > 7 days)	1b A	++
> Therapeutic usage for FNP	1a A	+/-
> Start related to chemotherapy and duration		
> Pegfilgrastim day 2	1b A	++
> Lipegfilgrastim day 2	1b A	++
> Filgrastim/Lenograstim from day 2–3 until ANC > 2–3 x 10 <sup>9</sup>	1b A	++

**Supplemental fig. 4.** Use of granulocyte colony-stimulating factors.

## References

- Oxford CEBM: Level of evidence, LoE, www.cebm.net.
- Empfehlungen Gynäkologische Onkologie Kommission Mamma, 2016, www.ago-online.de.
- Coleman R et al. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. *Lancet* 3;386[10001]:1353–61, 2015.
- Gnant M et al. The impact of adjuvant denosumab on disease-free survival: Results from 3,425 postmenopausal patients of the ABCSG-18 trial. *SABCS S2–02*, 2015.
- Hortobagyi GN et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial. *J Clin Oncol* 32:5s, 2014 (suppl; abstr LBA9500).
- Amadori D et al. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. *Lancet Oncol* 14[7]:663–670, 2013.
- Himelstein AL et al. CALGB 90604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer (abstr). *J Clin Oncol* 33, 2015 (suppl; abstr 9501).

- 8 Ibrahim MF, Mazzarello S, Shorr R, Vandermeer L, Jacobs C, Hilton J, Hutton B, Clemons M. Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis. *Ann Oncol* 2015; 26[11]:2205–13.
- 9 Fizazi K et al.: Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. *J Clin Oncol* 2009;27[10]:1564–1571.
- 10 Templeton AJ et al. Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: A noninferiority phase III trial (SAKK 96/12, REDUSE). *J Clin Oncol* 32:5s, 2014 (suppl; abstr TPS5095).
- 11 Runowcz CD, Leach CR, Henry L et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. *CA Cancer J Clin* 2016;66:43–73.
- 12 Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). *Breast*. 2014 Oct;23[5]:489–502.
- 13 Chan DS, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, Navarro Rosenblatt D, Thune I, Vieira R, Norat T. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. *Ann Oncol*. 2014 Oct;25[10]:1901–14.
- 14 Drukker CA, Elias SG, Nijenhuis MV, Wesseling J, Bartelink H, Elkhuizen P, Fowble B, Whitworth PW, Patel RR, de Snoo FA, van 't Veer LJ, Beitsch PD, Rutgers EJ. Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis. *Breast Cancer Res Treat*. 2014 Dec;148[3]:599–613. doi: 10.1007/s10549-014-3188-z. Epub 2014 Nov 21. Erratum in: *Breast Cancer Res Treat*. 2015 Jan;149[2]:567.
- 15 Fitzal F, Filipits M, Fesl C, Rudas M, Dubsy PC, Bartsch R, Regitnig P, Bauernhofer T, Greil R, Leitner G, Knauer M, Hubalek M, Fridrik MA, Herz W, Dietze O, Cowens JW, Ferree S, Nielsen TO, Gnant M. Predicting local recurrence using PAM50 in postmenopausal endocrine responsive breast cancer patients. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 1008).
- 16 Uth CC, Christensen MH, Oldenbourg MH, Kjær C, Garne JP, Teilum D, Kroman N, Tvedskov TF. Sentinel Lymph Node Dissection in Locally Recurrent Breast Cancer. *Ann Surg Oncol* 2015;22[8]:2526–31.
- 17 Aebi S, Gelber S, Anderson SJ, Láng I, Robidoux A, Martín M, Nortier JW, Paterson AH, Rimawi MF, Cañada JM, Thürlimann B, Murray E, Mamounas EP, Geyer CE Jr, Price KN, Coates AS, Gelber RD, Rastogi P, Wolmark N, Wapnir IL; CALOR investigators. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. *Lancet Oncol*. 2014 Feb;15[2]:156–63.
- 18 Aurilio G, Disalvatore D, Pruneri G, et al.: A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. *Eur J Cancer* 2014;50:277–289.
- 19 Jonat W, Kaufmann M, Blamey RW, et al.: A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and peri-menopausal patients with advanced breast cancer. *Eur J Cancer* 1995;31A:137–142.
- 20 Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Bartlett CH, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer, *N Engl J Med* 2015;373:209–219.

- 21 Gibson L, Lawrence D, Dawson C, Bliss J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. *Cochrane Database Syst Rev* 2009;[4]:CD003370;Di Leo A, Jerusalem G, Petruzelka L, et al.: Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. *J Clin Oncol* 2010;28:4594–4600.
- 22 Ellis MJ, Llombart-Cussac A, Feltl D, Dewar JA, Jasiówka M, Hewson N, Rukazenzov Y, Robertson JF. Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study. *J Clin Oncol*. 2015 Nov 10;33[32]:3781–7.
- 23 Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. *Lancet Oncol*. 2015 Jan;16[1]:25–35.
- 24 Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Bartlett CH, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer, *N Engl J Med* 2015;373:209–219.
- 25 Baselga J, Campone M, Piccart M, et al.: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med* 2012;366:520–529.
- 26 Martín M, Loibl S, von Minckwitz G, et al.: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. *J Clin Oncol* 2015;33:1045–1052.
- 27 Kaufman B, Mackey JR, Clemens MR, et al.: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. *J Clin Oncol* 2009;27:5529–5537.
- 28 Burstein HJ, Cirincione CT, Barry WT, Chew HK, Tolaney SM, Lake DE, Ma C, Blackwell KL, Winer EP, Hudis CA. Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). *J Clin Oncol*. 2014 Dec 10;32[35]:3959–66.
- 29 Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). *Breast*. 2014 Oct;23[5]:489–502.
- 30 Dear RF, McGeechan K, Jenkins MC, et al.: Combination versus sequential single agent chemotherapy for metastatic breast cancer. *Cochrane Database Syst Rev* 2013;12:Cd008792.
- 31 Guo X, Loibl S, Untch M, Möbus V, Schwedler K, Fasching PA, Barinoff J, Holms F, Thomssen C, Zahm DM, Kreienberg R, Hauschild M, Eidtmann H, Tauchert S, Mehta K, von Minckwitz G. Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-) Adjuvant Taxane-Based Therapy. *Breast Care (Basel)* 2011;6[4]: 279–283.
- 32 Twelves C, Jove M, Gombos A, Awada A. Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer. *Crit Rev Oncol Hematol* 2016;100:74–87.
- 33 Gligorov J, Doval D, Bines J, et al.: Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-

- negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2014;15:1351–1360.
- 34 Bidard FC, Peeters DJ, Fehm T, et al.: Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. *Lancet Oncol* 2014;15:406–414.
- 35 Bidard FC, Fehm T, Ignatiadis M, et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. *Cancer Metastasis Rev* 2013;32:179–188.
- 36 Wang X, Huang C, Li M, et al.: The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials. *Tumour Biol* 2014;35:4841–4848.
- 37 Clark O, Botrel TE, Paladini L, Ferreira MB. Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis. *Core Evid* 2014;9:1–11.
- 38 Li Q, Yan H, Zhao P, Yang Y, Cao B. Efficacy and Safety of Bevacizumab Combined with Chemotherapy for Managing Metastatic Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. *Sci Rep.* 2015;5:15746.
- 39 Von Minckwitz G, Puglisi F, Cortes J, et al.: Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. *Lancet Oncol* 2014;15:1269–1278.
- 40 Tutt A, Ellis P, Kilburn L, et al.: TNT: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). *San Antonio Breast Cancer Symposium 2014;abstr S3–01.*
- 41 Swain SM, Baselga J, Kim SB, et al.: Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. *N Engl J Med* 2015;372:724–734.
- 42 Dang C, Iyengar N, Datko F, D’Andrea G, Theodoulou M, Dickler M, Goldfarb S, Lake D, Fasano J, Fornier M, Gilewski T, Modi S, Gajria D, Moynahan ME, Hamilton N, Patil S, Jochelson M, Norton L, Baselga J, Hudis C. Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. *J Clin Oncol.* 2015;33[5]: 442–447.
- 43 Andersson M, López-Vega JM, Petit T, Zamagni C, Donica M, Kamber J, Perez EA. The co-administration of pertuzumab (P) and trastuzumab (T) as a single infusion, followed by vinorelbine (V), in first-line [1L] treatment of HER2-positive locally advanced or metastatic breast cancer (MBC) patients (pts): VELVET study interim analysis. *J Clin Oncol* 2015;33 suppl; abstr 586.
- 44 Verma S, Miles D, Gianni L, et al.: Trastuzumab emtansine for HER2-positive advanced breast cancer. *N Engl J Med* 2012;367:1783–1791.
- 45 Krop IE, Kim S-B, González-Martín A, et al.: Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2014;15:689–699.
- 46 Khan SA, Stewart AK, Morrow M: Does aggressive local therapy improve survival in metastatic breast cancer? *Surgery* 2002;132:620–626.
- 47 Badwe R, Hawaldar R, Nair N, Kaushik R, Parmar V, Siddique S, Budrukkar A, Mitra I, Gupta S. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. *Lancet Oncol.* 2015 Oct;16[13]:1380–8.
- 48 Rapiti E, Verkooijen HM, Vlastos G, et al.: Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. *J Clin Oncol* 2006;24:2743–2749.

- 49 Babiera GV, Rao R, Feng L, et al.: Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. *Ann Surg Oncol* 2006;13:776–782.
- 50 Howlader M, Heaton N, Rela M: Resection of liver metastases from breast cancer: towards a management guideline. *Int J Surg* 2011;9:285–291.
- 51 Abbott DE, Brouquet A, Mittendorf EA, Andreou A, Meric-Bernstam F, Valero V, Green MC, Kuerer HM, Curley SA, Abdalla EK, Hunt KK, Vauthey JN: Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. *Surgery* 2012;151:710–716.
- 52 Vertriest C, Berardi G, Tomassini F, Vanden Broucke R, Depypere H, Cocquyt V, Denys H, Van Belle S, Troisi RI. Resection of single metachronous liver metastases from breast cancer stage I-II yield excellent overall and disease-free survival. Single center experience and review of the literature. *Dig Surg*. 2015;32[1]:52–9.
- 53 Dittmar Y, Altendorf-Hofmann A, Schüle S, Ardelt M, Dirsch O, Runnebaum IB, Settmacher U. Liver resection in selected patients with metastatic breast cancer: a single-centre analysis and review of literature. *J Cancer Res Clin Oncol*. 2013;139[8]:1317–25.
- 54 Hoffmann RT, Jakobs TF, Kubisch CH, et al.: Radiofrequency ablation after selective internal radiation therapy with yttrium90 microspheres in metastatic liver disease – is it feasible? *Eur J Radiol* 2010;74:199–205.
- 55 Vogl TJ, Farshid P, Naguib NN, Zangos S: Thermal ablation therapies in patients with breast cancer liver metastases: a review. *Eur Radiol* 2013;23:797–804.
- 56 Rashid OM, Takabe K: The evolution of the role of surgery in the management of breast cancer lung metastasis. *J Thorac Dis* 2012;4:420–424.
- 57 Demmy TL: Optimal management of malignant pleural effusions (results of CALBG 30102). *J Natl Compr Canc Netw* 2012;10:975–982.
- 58 Sebastian M, Kuemmel A, Schmidt M, Schmittel A: Catumaxomab: a bispecific trifunctional antibody. *Drugs Today (Barc)* 2009;45:589–597.
- 59 Cozzi S, Montanara S, Luraschi A, et al.: Management of neoplastic pericardial effusions. *Tumori* 2010;96:926–929.
- 60 Kopp HG, Krauss K, Fehm T, et al.: Symptomatic bone marrow involvement in breast cancer – clinical presentation, treatment, and prognosis: a single institution review of 22 cases. *Anticancer Res* 2011;31:4025–4030.
- 61 Witzel I, Oliveira-Ferrer L, Pantel K, Müller V, Wikman H: Breast cancer brain metastases: Biology and new clinical perspectives. *Breast Cancer Research* 2016;18.
- 62 BMBC homepage: [Http://s605008600.Online.De/de/studien/brainmet.Php](http://s605008600.Online.De/de/studien/brainmet.Php).
- 63 Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M: Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. *J Clin Oncol* 2012;30:419–425.
- 64 Brown A, Asher AL, Ballman K, Farace E, Cerhan J, Anderson K, Carrero X, Berker F, Deming R, Burri S, Menard C, Chung C, Stieber V, Pollock BE, Galanis E, Buckner JC, Jaeckle KA: Ncctg n0574 (alliance): A phase III randomized trial of whole brain radiation therapy (wbrt) in addition to radiosurgery (srs) in patients with 1 to 3 brain metastases. *J Clin Oncol* 2015;33:Abstract LBA 4.
- 65 Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, Rowley H, Kundapur V, DeNittis A, Greenspoon JN, Konski AA, Bauman GS, Shah S, Shi W, Wendland M, Kachnic L, Mehta MP: Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (rtog 0933): A phase II multi-institutional trial. *J Clin Oncol* 2014;32:3810–3816.

**Supplementary Material**

- 66 Witzel I, Kantelhardt EJ, Milde-Langosch K, Ihnen M, Zeitz J, Harbeck N, Janicke F, Muller V: Management of patients with brain metastases receiving trastuzumab treatment for metastatic breast cancer. *Onkologie* 2011;34:304–308.
- 67 Schjoeth-Eskesen C, Nielsen CH, Heissel S, Hojrup P, Hansen PR, Gillings N, Kjaer A: <sup>64</sup>Cu-labelled trastuzumab: Optimisation of labelling by dota and nodaga conjugation and initial evaluation in mice. *J Labelled Comp Radiopharm* 2015;58:227–233.
- 68 Perez EA, Awada A, O’Shaughnessy J, Rugo HS, Twelves C, Im SA, Gomez-Pardo P, Schwartzberg LS, Dieras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Cortes J: Etrintotecan pegol (nktr-102) versus treatment of physician’s choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (beacon): A randomised, open-label, multicentre, phase 3 trial. *Lancet Oncol* 2015;16:1556–1568.
- 69 Paluch-Shimon S, Pagani O, Partridge AH, Bar-Meir E, Fallowfield L, Fenlon D, Friedman E, Gelmon K, Gentilini O, Geraghty J, Harbeck N, Higgins S, Loibl S, Moser E, Peccatori F, Raanani H, Kaufman B, Cardoso F. Second international consensus guidelines for breast cancer in young women (BCY2). *Breast*. 2016 Apr;26:87–99.
- 70 Lambertini M, Ceppi M, Poggio F, Peccatori FA, Azim HA Jr, Ugolini D, Pronzato P, Loibl S, Moore HC, Partridge AH, Bruzzi P, Del Mastro L. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. *Ann Oncol*. 2015 Dec;26[12]:2408–19.
- 71 Zaenger D, Rabatic BM, Dasher B, Mourad WF. Is Breast Conserving Therapy a Safe Modality for Early-Stage Male Breast Cancer? *Clin Breast Cancer* 2016 Apr;16[2]:101–4.
- 72 Lim SZ, Ong KW, Tan BK, Selvarajan S, Tan PH. Sarcoma of the breast: an update on a rare entity. *J Clin Pathol* 2016 69[5]:373–81.
- 73 Naeim A, Henk HJ, Becker L, et al.: Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte-colony stimulating factors (G-CSF). *BMC Cancer* 2013;13:11.
- 74 Bondarenko I, Gladkov OA, Elaesser R, et al.: Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/ docetaxel chemotherapy. *BMC Cancer* 2013;13:386.
- 75 Roila F, Ruggeri B, Ballatori E, et al.: Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study. *J Clin Oncol* 2014;32:101–106.
- 76 Smith TJ, Temin S, Alesi ER, et al.: American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. *J Clin Oncol* 2012;30:880–887.
- 77 Leyland-Jones B, Semiglazov V, Pawlicki M, et al.: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. *J Clin Oncol* 2005;23:5960–5972.
- 78 Tonelli M, Hemmelgarn B, Reimann T, et al.: Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer. A meta-analysis. *CMAJ* 2009;180:E62–E71.
- 79 Glaspy J, Crawford J, Vansteenkiste J, et al.: Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. *Br J Cancer* 2010;102:301–315.
- 80 Moebus V, Jackisch C, Schneeweiss A, et al.: Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. *J Natl Cancer Inst* 2013;105:1018–1026.



**Supplementary Material**

- 81 Swain SM, Tang G, Geyer CE, et al.: Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node positive breast cancer: the NSABP B-38 trial. *J Clin Oncol* 2013;31:3197–3204.
- 82 Nitz U, Gluz O, Oberhoff C, et al.: Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer. *Ann Oncol* 2014;25:75–80.
- 83 Pallis AG, Ring A, Fortpied C, et al.: EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors. *Ann Oncol* 2011;22:1922–1926.
- 84 Keefe DL: Trastuzumab-associated cardiotoxicity. *Cancer* 2002;95:1592–1600.
- 85 Swain SM, Ewer MS, Cortés J, et al.: Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2- positive metastatic breast cancer in CLEOPATRA. *Oncologist* 2013;18:257–264.
- 86 Baselga J, Bradbury I, Eidtmann H, et al.: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO). *Lancet* 2012;379:633–640.
- 87 Koppelmans V, Breteler MM, Boogerd W, et al.: Late effects of adjuvant chemotherapy for adult onset non-CNS cancer; cognitive impairment, brain structure and risk of dementia. *Crit Rev Oncol Hematol* 2013;88:87–101.
- 88 Smith IE, Pierga JY, Biganzoli L, Cortés-Funes H, Thomssen C, Pivot X, Fabi A, Xu B, Stroyakovskiy D, Franke FA, Kaufman B, Mainwaring P, Pienkowski T, De Valk B, Kwong A, González-Trujillo JL, Koza I, Petrakova K, Pereira D, Pritchard KI; ATHENA Study Group: First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. *Ann Oncol* 2011;22:595–602.
- 89 Biganzoli L, Di Vincenzo E, Jiang Z, Lichinitser M, Shen Z, Delva R, Bogdanova N, Vivanco GL, Chen Z, Cheng Y, Just M, Espié M, Vinholes J, Hamm C, Crivellari D, Chmielowska E, Semiglazov V, Dalenc F, Smith I: First-line bevacizumab-containing therapy for breast cancer: results in patients aged  $\geq 70$  years treated in the ATHENA study. *Ann Oncol* 2012;23:111–118.
- 90 Rugo HS, Hortobagyi GN, Yao J, Pavel M, Ravaud A, Franz D, Ringeisen F, Gallo J, Rouyrre N, Anak O, Motzer R: Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. *Ann Oncol* 2016;27:519–525.